Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMGN NYSE:LLY NASDAQ:MRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$339.30+0.6%$345.10$267.83▼$391.29$182.10B0.442.82 million shs1.57 million shsLLYEli Lilly and Company$1,066.59+2.4%$942.87$623.78▼$1,133.95$980.96B0.483.50 million shs3.47 million shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/A5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+0.56%+3.98%-1.91%-9.46%+25.05%LLYEli Lilly and Company+2.37%+6.11%+15.81%+5.76%+47.26%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$339.30+0.6%$345.10$267.83▼$391.29$182.10B0.442.82 million shs1.57 million shsLLYEli Lilly and Company$1,066.59+2.4%$942.87$623.78▼$1,133.95$980.96B0.483.50 million shs3.47 million shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/A5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+0.56%+3.98%-1.91%-9.46%+25.05%LLYEli Lilly and Company+2.37%+6.11%+15.81%+5.76%+47.26%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMGNAmgen 2.48Hold$355.194.68% UpsideLLYEli Lilly and Company 2.87Moderate Buy$1,220.3714.42% UpsideMRTXMirati Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AMGN, LLY, and MRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026LLYEli Lilly and Company The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1,283.005/21/2026LLYEli Lilly and Company Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$1,350.005/21/2026LLYEli Lilly and Company Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/21/2026LLYEli Lilly and Company Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price Target$1,300.00 ➝ $1,330.005/20/2026AMGNAmgen ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$400.00 ➝ $375.005/19/2026LLYEli Lilly and Company Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/14/2026AMGNAmgen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$432.00 ➝ $427.005/13/2026AMGNAmgen Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$410.00 ➝ $390.005/7/2026AMGNAmgen Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/7/2026LLYEli Lilly and Company Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price Target$880.00 ➝ $900.005/5/2026AMGNAmgen Erste Group BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMGNAmgen$37.22B4.92$34.00 per share9.98$17.03 per share19.92LLYEli Lilly and Company$65.18B15.41$25.74 per share41.44$33.13 per share32.19MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMGNAmgen$7.71B$14.3723.6114.403.3920.96%137.41%13.28%8/4/2026 (Estimated)LLYEli Lilly and Company$20.64B$28.1537.8924.111.1334.98%105.77%23.76%8/5/2026 (Estimated)MRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/ALatest AMGN, LLY, and MRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026AMGNAmgen$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion4/30/2026Q1 2026LLYEli Lilly and Company$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMGNAmgen$10.082.97%+8.27%70.15%14 YearsLLYEli Lilly and Company$6.920.65%+15.18%24.58%11 YearsMRTXMirati TherapeuticsN/AN/AN/AN/AN/ALatest AMGN, LLY, and MRTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/4/2026LLYEli Lilly and Companyquarterly$1.730.69%5/15/20265/15/20266/10/20263/4/2026AMGNAmgenquarterly$2.523.09%5/15/20265/15/20266/5/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMGNAmgen5.651.261.01LLYEli Lilly and Company1.261.501.10MRTXMirati TherapeuticsN/A7.547.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMGNAmgen76.50%LLYEli Lilly and Company82.53%MRTXMirati TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAMGNAmgen0.85%LLYEli Lilly and Company0.14%MRTXMirati Therapeutics3.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMGNAmgen31,500539.69 million535.10 millionOptionableLLYEli Lilly and Company50,000941.74 million940.42 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionNo DataAMGN, LLY, and MRTX HeadlinesRecent News About These CompaniesBMS removes 2 clinical programs from pipeline, one from Mirati and another from ExscientiaOctober 31, 2025 | fiercebiotech.comFMirati's Flagship Drug Faces Mounting Pressure from Lilly's New TherapySeptember 4, 2025 | aktiencheck.deAMirati Therapeutics Stock Price HistoryMay 26, 2025 | investing.comNew GTPase KRAS mutant inhibitors disclosed in Mirati patentDecember 12, 2024 | bioworld.comBMirati Therapeutics Receives Untitled Letter from OPDP for Overstating Cancer Drug EfficacyOctober 15, 2024 | policymed.comPPharma M&A rumour mill grinds out Mirati's name againAugust 16, 2024 | pharmaphorum.comPMirati's Charles Baum takes the helm at Terremoto BiosciencesJuly 25, 2024 | fiercebiotech.comFMirati Therapeutics gets grant for combination therapy for treating kras G12C cancersApril 17, 2024 | pharmaceutical-technology.comPMirati Therapeutics gets grant for combination therapy for treating kras G12C cancersApril 17, 2024 | pharmaceutical-technology.comPHow this insider trader nailed every single stock tradeApril 5, 2024 | finbold.comFThe workforce reduction at Mirati Therapeutics will take place over the next year and impacts more than 400 employees.April 3, 2024 | sandiegouniontribune.comSMirati Therapeutics files patent for inhibitors of KRAS g12dMarch 26, 2024 | pharmaceutical-technology.comPBristol Myers Squibb cuts hundreds of Mirati staffers months after closing $5.8B buyoutMarch 26, 2024 | fiercepharma.comFBristol Myers Squibb concludes acquisition of Mirati TherapeuticsJanuary 26, 2024 | medicaldialogues.inMBristol Myers Squibb completes acquisition of Mirati TherapeuticsJanuary 25, 2024 | pharmabiz.comPMirati Therapeutics Receives Marketing Authorization For KRAZATI From European CommissionJanuary 10, 2024 | markets.businessinsider.comEuropean Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationJanuary 10, 2024 | finance.yahoo.comMirati Therapeutics Inc [MRTX] Stock sold by Insider Christensen Jamie for $0.14 millionJanuary 2, 2024 | knoxdaily.comKEvaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers AcquisitionDecember 25, 2023 | seekingalpha.comBristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 blnDecember 22, 2023 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesApple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026Industrial Chips Are in Rally Mode—5 Ways to PlayBy Thomas Hughes | April 27, 2026What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Amazon’s Earnings Just Sent the Stock to New Highs—What’s Next?By Sam Quirke | April 30, 2026Intel Stock Hits All-Time Highs: Is the Turnaround Priced In?By Sam Quirke | April 24, 2026AMGN, LLY, and MRTX Company DescriptionsAmgen NASDAQ:AMGN$339.30 +1.88 (+0.56%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$340.28 +0.98 (+0.29%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.Eli Lilly and Company NYSE:LLY$1,066.59 +24.94 (+2.39%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$1,065.00 -1.59 (-0.15%) As of 05/22/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
